BURLINGTON, Mass., Oct. 2, 2013 /PRNewswire/ -- Decision Resources Group Analyst Dr. Andreia Ribeiro will be moderating a panel focused on the role of pharmaeconomics in the decision making process for successful market access in Mexico.  An expert on market access issues in Latin America, Dr. Ribeiro will be available for further discussion at the Decision Resources Group Booth #8. The conference will take place on October 8 and 9, 2013 at the Intercontinental Presidente Hotel in Mexico City, Mexico.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36768LOGO )

The panel discussion, entitled "The role of pharmaeconomics in the decision making process for successful market access in Mexico," will focus on:

  • Analysis of the current HTA models in LATAM (Brazil, Mexico and Argentina) and the increased role of pharmacoeconomics in the formulary access decision making.
  • Are we implementing the correct models?
  • Analysis of how health economic evaluations are used by the different healthcare institutions in Mexico for inclusion of new products in the national and institutional formularies

Panelists include:

Rosa Maria Galindo Suarez, Prioritization Deputy Director of the General Health Council
Arely Edith Lemus Carmona, Manager Health Economics and Outcomes Research in Health at Novartis
Hernan Chivardy Olmos, Access Manager Federal Basic Tables at Specialized Drug Group
Pablo Anaya Gomez Montenegro, Manager Health Economics at Novartis Oncology
Joselyn Ramirez, Pharmacoeconomics Manager at Eli Lilly and Company

About the Market Access Mexico Conference:
Learn from the major institutions national health to build a successful market access strategy.  This is the 4th annual conference of Mexico in the area of ​​Market Access pharmaceutical industry. More than 230 executives and 27 speaker experts will gather in Mexico City to identify market access strategies that ensure institutional benefits by 2014.  For more information and to register for the event, please visit:

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:
Kelly Espinola
Decision Resources Group


SOURCE Decision Resources Group

Gastroenterologists Unlikely To Use Celltrion/Hospira's Infliximab Biosimilar Due To Lack Of Clinical Data In Inflammatory Bowel Disease

View Now